Timothy Michael O’Brien

Levin Papantonio Rafferty shareholder Timothy O'Brien is a board-certified civil trial attorney who concentrates his practice in the areas of mass tort litigation, product liability, personal injury, wrongful death, and transactional liability. Mr. O'Brien is rated "A-V Preeminent" by the prestigious Martindale-Hubbell lawyer peer-rating service (the "A-V Preeminent" rating is the highest rating an attorney can receive). In September 2018, Mr. O’Brien was appointed by the United States Southern District of Ohio as Co-Lead Counsel for the Plaintiffs Steering Committee in MDL No. 2846, In re Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation. In January 2021, he was appointed by the United States District Court for the District of New Jersey to the Plaintiffs Executive Committee and as the Discovery Chair in MDL No. 2973, In re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation.

He previously served as Plaintiffs Steering Committee Lead Counsel for MDL No. 1789, In re Fosamax Products Liability Litigation, as co-chair of the Discovery Committee In re Yasmin and Yaz (Drospirenone) Products Liability Litigation, MDL No. 2100, on the Plaintiffs Executive Committee in In re Invokana (Canagliflozin Products Liability Litigation, MDL No. 2750, as national co-lead counsel in In re Cisco Systems Securities Litig., MDL No. 1527, as Discovery co-chair in In re Accutane Products Liab. Litig., MDL No. 1626, as Discovery co-chair in In re Medtronic, Inc., Implantable Defibrillators Product Liab. Litig., MDL No. 1726, as a member of the Plaintiffs Steering Committee in In re Guidant Corp. Implantable Defibrillators Product Liab. Litig., MDL No. 1708, and served on the discovery committee of In re Phenylpropanolamine ("PPA") Products Liab. Litig. , MDL No. 1407.

He has been interviewed by and extensively quoted in The Wall Street Journal, The New York Times, The Pink Sheet, The Associated Press, Reuters, and Bloomberg News.